Retinal diseases

Structure of the eye
#Mogrify #Preclinical development #Retinal diseases #Transcriptomics

MOGRIFY-derived transcription factors preserve functional vision

Mogrify will present preclinical proof-of-concept data at FLORetina-ICOOR 2026 in support its first-in-class therapy designed to protect and regenerate the retina in patients with retinal disorders.  The company’s lead programme uses transcription factor-mediated direct reprogramming to convert müller glial cells into functional photoreceptors within the retina.  … Read More

#News

Structure of the eye
#Breye Therapeutics #Financing #Ophthalmology #Retinal diseases

Breye raises €67.5 million for retinal disease therapies

Breye Therapeutics has closed an over-subscribed €67.5 million Series A financing round.   The round was co-led by new investor Mission BioCapital and existing investor Novo Holdings, with participation from existing investor Sound Bioventures and additional new investors including the Ljungström family office, Innovestor Life Science, EIFO, Catalyze Capital, Modi Ventures… Read More

#Business & Investment #News